Methylthioninium chloride - TauRx

Drug Profile

Methylthioninium chloride - TauRx

Alternative Names: Methylene blue - TauRx; MTC; Rember; TRx-0014; TRx-014

Latest Information Update: 12 Nov 2012

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator TauRx Therapeutics
  • Developer TauRx Therapeutics; University of Aberdeen
  • Class Antidementias; Antiparkinsonians; Phenothiazines; Small molecules
  • Mechanism of Action Synuclein inhibitors; Tau protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Alzheimer's disease; Parkinson's disease

Most Recent Events

  • 12 Nov 2012 Discontinued - Phase-II for Alzheimer's disease in Singapore (PO)
  • 12 Nov 2012 Discontinued - Phase-II for Alzheimer's disease in United Kingdom (PO)
  • 12 Nov 2012 Discontinued - Preclinical for Parkinson's disease in Singapore (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top